
Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~ ~ No Clinical Safety or Efficacy Issues Identified; No Additional Studies Required for PEDMARK™ ~ ~ …